六七年来，只有他一个人说他汀类药物（Crestor、Ator、Lipitor）是被禁止的，Controloc（泮托拉唑）也是被禁止的。
原始表述
قلت الكلام ده من ست سبع سنين لوحدي كنت لوحدي بقول الستاتنز والي هم اللي هم الكريستور والاتور والليبيتور والحاجات دي كنت لوحدي بقول ممنوعه وبقول الكونترولوكس ممنوع وكنت لوحدي دي ماشي
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
六七年来，只有他一个人说他汀类药物（Crestor、Ator、Lipitor）是被禁止的，Controloc（泮托拉唑）也是被禁止的。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live! مقاومة الأنسولين ٢ (打开来源)
- 发布日期
- 2025年7月1日
- 时间戳
- 1:31:13 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Transcript is YouTube CC or machine-generated (no timestamps); wording may contain speech-recognition errors. Speaker attribution within live streams/podcasts is not marked in the transcript; the excerpt was judged to be Elawady's own speech from context. Recurrence = number of archive transcripts matching the keyword pattern ['ستاتين|الستاتنز|ليبيتور|كريستور'] (approximate; includes re-uploads/clips; 29 distinct text passages).
- 所声称的机制
Not stated in this excerpt.
- 所声称的健康影响
Not specified.
- 涉及人群
Everyone.
- Elawady 设定的地域限制
none found; he does not limit this statement to a country or to a production system
来源版本存在差异
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live! لايف هزار (打开来源)
- 发布日期
- 2025年9月1日
- 时间戳
- 无（转录文本不含时间信息）
- 归属的不确定性
- Further video in which the same statement recurs; no excerpt recorded. Archive transcript without timestamps.
科学评估
错误 – 该说法与可靠证据相矛盾。
证据确定性: 高 – 进一步研究极不可能改变该评估。
1. 说法是什么？
Statins (rosuvastatin/Crestor, atorvastatin/Ator, Lipitor) are forbidden, and Controloc (pantoprazole) is forbidden; he says he alone said this for six or seven years.
2. 哪些内容可证实是正确的？
Statins are not free of harm: they cause a small excess of mostly mild muscle pain, mainly in the first year (absolute excess 11 per 1000 person-years; only about 1 in 15 muscle complaints on statins was due to the statin) (I-INTB-19), and a small increase in diabetes risk (OR 1.09; one extra case per 255 people treated for 4 years) (I-INTB-20). Whether a low-risk person should take a statin is a legitimate individual decision. In absolute terms the benefit is modest for many people: across 21 trials statins reduced death by 0.8, heart attacks by 1.3 and strokes by 0.4 percentage points (I-SRC-111), and a 2026 guideline suggests stopping statins in older adults at the end of life (I-SRC-132).
3. 哪些内容是错误或夸大的？
A general ban is contradicted by the evidence: per 1 mmol/L LDL reduction, major vascular events fell by about a fifth (RR 0.78) and all-cause mortality by 10% (RR 0.90), with no increase in cancer (I-INTB-18). The authors of both harm meta-analyses concluded that the risks are much lower than the cardiovascular benefits (I-INTB-19, I-INTB-20). For acid blockers see C-PPI-10. In blinded trials with 123,940 participants, only 4 of 66 side effects listed in statin labels were more common on statins (mainly liver-test changes, absolute excess 0.13% per year); there was no support for cognitive problems, depression, sleep disturbance or neuropathy (I-SRC-110).
4. 哪些内容仍不明确？
The claim that he was the only person criticising statins cannot be verified.
5. 哪些研究支持该说法？
I-INTB-19, I-INTB-20 (small harms); I-SRC-111 (modest absolute benefit); I-SRC-132 (stop at end of life).
6. 哪些研究与该说法相矛盾？
7. 对德国和欧洲而言情况如何？
UK NICE guideline NG238 (fetched 2026-10-26) recommends atorvastatin for primary prevention at 10-year QRISK3 of 10% or more and states that statin treatment for secondary prevention should not be delayed; European ESC/EAS guidance could not be fetched for this review.
8. 关于埃及的已知情况是什么？
Cardiovascular disease is a leading cause of death in Egypt (general knowledge; not sourced here); the same trial evidence applies.
9. 合理的实际结论是什么？
曾发生心脏病发作或中风的人，或处于高风险的人，未经医生指导不应停用他汀类药物。副作用可以与医生讨论。
评估详情
- 证据确定性的依据
- 来源质量
Machine transcript of a live stream; wording may contain recognition errors; meaning checked in context.
- 地区可推广性
High.
- 个体例外情况
Absolute benefit depends on baseline cardiovascular risk; in people at very low risk the benefit is small and an individual decision with a physician is appropriate.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
已被科学证据否定 – 高质量证据显示情况恰恰相反，或该说法与已确立的生理学知识相矛盾。
研究问题: Should statins (and pantoprazole) be forbidden for everyone, i.e. do their harms outweigh their benefits in people for whom they are prescribed?
研究问题详解 (PICO)
- 人群
- Adults prescribed statins (primary and secondary prevention)
- 干预或暴露
- Statin therapy
- 对照
- Placebo / no statin
- 地域范围
- universal biology
- 结局指标
- Major vascular events
- All-cause mortality
- Adverse effects
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
How much statins help in absolute terms
Byrne P et al.. JAMA Intern Med 2022 · PMID 35285850 · DOI 10.1001/jamainternmed.2022.0134 Meta分析已核查摘要新增Meta-analysis of absolute statin effects.
- 实际结果
- ARR all-cause mortality 0.8%, MI 1.3%, stroke 0.4% (NNT about 125, 77, 250).
- 方法学质量
- moderate
- 相关性
- direct; supports individual decisions in low-risk people
- 局限
- Heterogeneity.
Statins slightly raise diabetes risk
Statins and incident diabetes.
- 实际结果
- OR 1.09; one extra case per 255 treated for 4 years.
- 方法学质量
- high
- 相关性
- direct for a real harm
- 局限
- Small absolute risk.
When older adults can stop statins
Thompson W et al.. Can Fam Physician 2026 · PMID 42728062 · DOI 10.46747/cfp.7209534 指南 / 立场声明已核查摘要新增2026 deprescribing guideline for adults >=65.
- 实际结果
- Suggests deprescribing at end of life; continuing for primary and secondary prevention otherwise.
- 方法学质量
- guideline (GRADE)
- 相关性
- direct
- 局限
- Abstract only.
哪些证据不支持该说法？
Statins: what 26 trials show
CTT Collaboration, Baigent C et al.. Lancet 2010 · PMID 21067804 · DOI 10.1016/S0140-6736(10)61350-5 Meta分析全文，含结构化偏倚风险评估CTT individual-participant meta-analysis (170,000).
- 实际结果
- Per 1 mmol/L LDL reduction: major vascular events RR 0.78, all-cause mortality RR 0.90; no cancer increase.
- 方法学质量
- high
- 相关性
- direct
- 局限
- Trial populations.
Most side effects listed for statins are not caused by them
Cholesterol Treatment Trialists' (CTT) Collaboration. Lancet 2026 · PMID 41655587 · DOI 10.1016/S0140-6736(25)01578-8 Meta分析已核查摘要新增CTT 2026 blinded IPD meta-analysis of label-listed side effects.
- 实际结果
- Only 4 of 66 listed outcomes confirmed; liver-test abnormalities excess 0.13%/year; no support for cognitive impairment, depression, sleep disturbance, neuropathy.
- 方法学质量
- high
- 相关性
- direct for harms
- 局限
- Rare events may be missed.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Statins are beneficial for people at increased cardiovascular risk; harms are real but small; decisions in low-risk or end-of-life patients are individual.
为什么有些研究权重更大
IPD meta-analyses of blinded RCTs (CTT) carry most weight; overlapping CTT analyses share trials and are counted as one body of evidence.
因果关系是否已确立？ 是，已确立 Randomised blinded trials.
仍存在的不确定性
Benefit size in very low-risk people and very old adults.
合理的结论
A blanket ban on statins contradicts high-quality randomised evidence; the defensible kernel is that absolute benefit varies and some people (low risk, end of life) may reasonably decide not to take them.
为什么研究结果看起来互相矛盾？
这是否取决于国家？
- 一般生物学效应
- Universal pharmacology.
- 饮食习惯
- Not applicable.
- 食品原产地
- Not applicable.
- 污染物
- Not applicable.
- 本国生产条件
- Not applicable.
- 法律规则
- Prescription medicines; NICE NG238 recommends statins by risk.
- 实际监测数据
- No Egyptian statin outcome data reviewed.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- NNT from reported ARR – NNT about 125 (death), 77 (MI), 250 (stroke) over trial follow-up 已重新计算
- Absolute excess per year and RR CI symmetry – Transaminases +0.08, other LFT +0.05, oedema +0.07 points/year; CIs symmetric 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Major vascular events with statin therapy
- 起始等级
- 高（随机试验）
- 结果
- 高
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- NICE: NG238 Cardiovascular disease: risk assessment and reduction, including lipid modification (2023) · 原始文献
Offer atorvastatin 20 mg for primary prevention with QRISK3 >=10%; do not delay statin treatment for secondary prevention; do not stop statins because of a rise in blood glucose or HbA1c; check creatine kinase for unexplained muscle symptoms. - ESC/EAS: 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias (2025) · 原始文献 无法获取；内容未采用
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| PubMed | 2026年10月26日 | Cholesterol Treatment Trialists statin adverse events randomised trials meta-analysis 2025 | 双向 | 1 | |
| PubMed | 2026年10月26日 | N-of-1 trial statin nocebo SAMSON side effects | 反对性证据 | 1 | |
| PubMed | 2026年10月26日 | statins primary prevention absolute risk reduction relative risk meta-analysis JAMA Intern Med | 支持性证据 | 1 | |
| Europe PMC | 2026年10月26日 | (statin* AND (discontinuation OR "stopping") AND (cardiovascular events OR mortality) AND (cohort)) AND PUB_YEAR:[2016 TO 2026] | 反对性证据 | 8805 | |
| PubMed | 2026年10月26日 | AGA clinical practice update deprescribing proton pump inhibitors | 双向 | 1 | |
| PubMed | 2026年10月26日 | 2025 Focused Update 2019 ESC/EAS Guidelines management of dyslipidaemias | 指南 | 15 | |
| Europe PMC | 2026年10月26日 | (statin*) AND ("primary prevention") AND ("Cochrane Database Syst Rev" OR "meta-analysis") AND ("adverse events" OR harms OR "absolute risk") | 支持性证据 | 3472 | |
| NICE / ESC / OUP websites | 2026年10月26日 | NICE NG238 recommendations; ESC/EAS 2025 focused update (EHJ and Atherosclerosis full texts returned 403; escardio page 404) | 指南 | 3 |
核查深度如何？
6 项相关研究：2 项核查了全文（其中 2 项进行了结构化偏倚风险评估），4 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
通俗解释
Elawady 医生说，Crestor 和 Lipitor 等他汀类药物是被禁止的。纳入约 170,000 人的大型试验显示，他汀类药物可以预防心脏病发作和中风，并降低死亡风险。他汀类药物确实有副作用：少数人会出现肌肉疼痛，糖尿病风险也会略有升高。对高风险人群而言，益处远大于害处。对风险很低的人，应与医生共同做出决定。
与该说法相关的研究
支持该说法的研究 (0)
该组中没有研究。
与该说法相矛盾或限制该说法的研究 (2)
-
Statins: what 26 trials show
CTT Collaboration, Baigent C et al.. Lancet 2010 · PMID 21067804 · DOI 10.1016/S0140-6736(10)61350-5Meta分析独立交叉核查全文，含结构化偏倚风险评估★ 关键研究Each 1 mmol/L LDL reduction cut major vascular events by about a fifth and deaths by 10%, without more cancer.
Statins reduce vascular events and mortality.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Assess statin efficacy and safety
- 研究是如何开展的？
IPD meta-analysis
- 研究了多少人、动物或样本？
about 170,000
- 实际发现了什么？
Fewer heart attacks, strokes and deaths
- 观察到的效应有多大？
RR 0.78 per mmol/L for major vascular events; 2.8% vs 3.6% events per year (statin vs control)
- 研究结果对日常生活意味着什么？
Statins prevent heart attacks and strokes; the absolute gain is larger the higher the person's risk.
- 该研究有哪些局限？
Most trials industry-funded; data from 3 trials unavailable; only severe muscle damage (rhabdomyolysis) assessed
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'statins are forbidden'.
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Does not decide whether a specific low-risk person needs a statin.
-
Most side effects listed for statins are not caused by them
Cholesterol Treatment Trialists' (CTT) Collaboration. Lancet 2026 · PMID 41655587 · DOI 10.1016/S0140-6736(25)01578-8Meta分析独立交叉核查已核查摘要★ 关键研究In blinded trials with 124,000 people, only a few listed side effects (mainly liver-test changes) were more common on statins, and only slightly.
Only few label-listed harms confirmed in blinded trials; absolute excess small.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Check statin side effects
- 研究是如何开展的？
Meta-analysis of blinded trials
- 研究了多少人、动物或样本？
123,940 participants
- 实际发现了什么？
Only 4 of 66 listed harms confirmed; small excess
- 观察到的效应有多大？
Liver tests +0.13% per year
- 研究结果对日常生活意味着什么？
Statins are safer than labels suggest
- 该研究有哪些局限？
Rare events may be missed
- 它对 Elawady 的具体说法说明了什么？
Contradicts a ban
- 研究结果是否适用于德国和欧洲？
High
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (4)
-
Do statins cause muscle pain?
Cholesterol Treatment Trialists' Collaboration. Lancet 2022 · PMID 36049498 · DOI 10.1016/S0140-6736(22)01545-8Meta分析独立交叉核查全文，含结构化偏倚风险评估Statins cause a small excess of mild muscle pain, mostly in year 1; most muscle complaints are not caused by the statin.
Real but small muscle-symptom risk.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Quantify statin muscle effects
- 研究是如何开展的？
IPD meta-analysis
- 研究了多少人、动物或样本？
154,664 participants in 23 double-blind trials
- 实际发现了什么？
Small excess, mainly year 1
- 观察到的效应有多大？
RR 1.03; 11/1000 person-years
- 研究结果对日常生活意味着什么？
Muscle aches on statins are usually not from the statin, but a few are.
- 该研究有哪些局限？
Different trials recorded muscle symptoms differently; creatine kinase rarely measured
- 它对 Elawady 的具体说法说明了什么？
Acknowledges a real side effect; contradicts banning statins.
- 研究结果是否适用于德国和欧洲？
High
-
Statins slightly raise diabetes risk
Sattar N et al.. Lancet 2010 · PMID 20167359 · DOI 10.1016/S0140-6736(09)61965-6Meta分析独立交叉核查已核查摘要About one extra diabetes case per 255 people treated for 4 years.
Small diabetes risk; benefit outweighs in moderate/high risk.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test statin-diabetes link
- 研究是如何开展的？
Meta-analysis of RCTs
- 研究了多少人、动物或样本？
91,140
- 实际发现了什么？
9% higher risk
- 观察到的效应有多大？
OR 1.09; NNH 255 over 4 years
- 研究结果对日常生活意味着什么？
Statins have a small diabetes risk that is usually outweighed by fewer heart attacks.
- 该研究有哪些局限？
Abstract only
- 它对 Elawady 的具体说法说明了什么？
Supports that statins are not harmless; contradicts a ban.
- 研究结果是否适用于德国和欧洲？
High
-
How much statins help in absolute terms
Byrne P et al.. JAMA Intern Med 2022 · PMID 35285850 · DOI 10.1001/jamainternmed.2022.0134Meta分析独立交叉核查已核查摘要Statins lowered death by 0.8, heart attacks by 1.3 and strokes by 0.4 percentage points over the trials.
Absolute benefit modest (NNT ~125 for death), but positive; supports shared decisions, not a ban.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Quantify absolute statin benefit
- 研究是如何开展的？
Meta-analysis
- 研究了多少人、动物或样本？
21 trials
- 实际发现了什么？
Modest absolute but real reductions
- 观察到的效应有多大？
ARR 0.8% death; 1.3% MI; 0.4% stroke
- 研究结果对日常生活意味着什么？
Benefit depends on personal risk
- 该研究有哪些局限？
Heterogeneity
- 它对 Elawady 的具体说法说明了什么？
Supports individual choice, not a ban
- 研究结果是否适用于德国和欧洲？
High
-
When older adults can stop statins
Thompson W et al.. Can Fam Physician 2026 · PMID 42728062 · DOI 10.46747/cfp.7209534指南 / 立场声明独立交叉核查已核查摘要A 2026 guideline suggests stopping statins near the end of life but continuing them in other older adults.
Stopping statins is appropriate at end of life; otherwise continue.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Guide statin stopping in older people
- 研究是如何开展的？
GRADE guideline
- 研究了多少人、动物或样本？
Adults 65+
- 实际发现了什么？
Stop at end of life; otherwise continue
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Stopping is an individual medical decision
- 该研究有哪些局限？
Abstract only
- 它对 Elawady 的具体说法说明了什么？
Partly fits (some can stop), but not a ban
- 研究结果是否适用于德国和欧洲？
Moderate
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
UK NICE guideline NG238 (fetched 2026-10-26) recommends atorvastatin for primary prevention at 10-year QRISK3 of 10% or more and states that statin treatment for secondary prevention should not be delayed; European ESC/EAS guidance could not be fetched for this review.
埃及
Cardiovascular disease is a leading cause of death in Egypt (general knowledge; not sourced here); the same trial evidence applies.
在我的国家适用什么？
一般科学评估
错误 这一说法是错误的：他汀类药物有轻微但真实的副作用，但可以预防心脏病发作、中风和死亡；低风险者是否服用是个人决定，而不是禁止的理由。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.. CTT Collaboration, Baigent C et al.. Lancet 2010 · PMID 21067804 · DOI 10.1016/S0140-6736(10)61350-5
- Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.. Cholesterol Treatment Trialists' (CTT) Collaboration. Lancet 2026 · PMID 41655587 · DOI 10.1016/S0140-6736(25)01578-8
- Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.. Cholesterol Treatment Trialists' Collaboration. Lancet 2022 · PMID 36049498 · DOI 10.1016/S0140-6736(22)01545-8
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.. Sattar N et al.. Lancet 2010 · PMID 20167359 · DOI 10.1016/S0140-6736(09)61965-6
- Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis.. Byrne P et al.. JAMA Intern Med 2022 · PMID 35285850 · DOI 10.1001/jamainternmed.2022.0134
- Deprescribing statins for adults 65 years of age and older: Evidence-based clinical practice guideline.. Thompson W et al.. Can Fam Physician 2026 · PMID 42728062 · DOI 10.46747/cfp.7209534